Article
Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial.
Acta oncologica (Stockholm, Sweden) - 1 Sept 2018
Brøndum Line, Alsner Jan, Sørensen Brita Singers, Maare Christian, Johansen Jørgen, Primdahl Hanne, Evensen Jan Folkvard, Kristensen Claus Andrup, Andersen Lisbeth Juhler, Overgaard Jens, Eriksen Jesper Grau
Abstract excerpt
PURPOSE: To study the associations between development of moderate to severe skin rash, clinical outcome, and single nucleotide polymorphisms (SNPs) in candidate genes in head and neck cancer patients from the DAHANCA 19 trial receiving the EGFR-inhibitor zalutumumab concurrently with radiation treatment. MATERIAL AND METHODS: 310 patients were included from the zalutumumab-arm of the DAHANCA 19 study. Nine SNPs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.